Dr. Mehdi Nezafati, CEO of Abian Darou, announced the company’s plans to commence the export of its pharmaceutical supplements in the second half of 2025. This milestone marks a significant step forward in the company’s strategic expansion into international markets.
According to the Public Relations Department of Golrang Pharmaceutical Group, Abian Darou has been operating in Iran’s pharmaceutical sector for nearly 14 years. The company recently inaugurated a new manufacturing facility in Hamedan Province. Established less than 18 months ago, the site is dedicated exclusively to the production of dietary and pharmaceutical supplements.
Expanding Product Portfolio
Dr. Nezafati highlighted the company’s current product portfolio, which includes:
-
Uniflex and Uniferro in the orthopedics category,
-
Exermizing in the dermatology segment,
-
Akym and ActivWoman as general multivitamin supplements,
-
Specialized formulas such as Uniform Active Iron, designed for iron deficiency,
-
Products tailored for women’s health, including ActivWoman.
He further revealed that over 10 new products are expected to be launched by the end of the current and upcoming fiscal year, as part of the company’s R&D-driven growth plan.
A Focus on Therapeutic Diversity
Dr. Nezafati highlighted the company’s diverse product portfolio, stating:
“In the field of orthopedics, we produce Uniflex and Uniferro; in dermatology, Exermizing; and for general multivitamin support, we offer Actim and Actiwomen. We also produce specialized formulations such as Acti Iron for iron deficiency, and women’s health supplements under the Actiwomen line.”
He further noted that the company is actively expanding its product portfolio, with plans to introduce over 10 new products by the end of this year and into 2025. The company’s core strategy centers around research and development of innovative formulations across various health categories.
Export Strategy and Global Outreach
Abian Darou has laid the groundwork for exports to three international regions, with initial shipments expected in the second half of 2025.
“We are entering global markets with strong confidence in our quality and innovation,” said Dr. Nezafati.
Employment and Industry Impact
The newly launched facility has already created employment for approximately 200 personnel, and the company welcomes collaboration with young pharmaceutical professionals.
Dr. Nezafati concluded: “By leveraging the expertise of local scientists and specialists, Abian Darou is committed to playing a pivotal role in the advancement of Iran’s pharmaceutical and nutraceutical industries.”
